Correlation Between Phathom Pharmaceuticals and Arcutis Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Phathom Pharmaceuticals and Arcutis Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Phathom Pharmaceuticals and Arcutis Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Phathom Pharmaceuticals and Arcutis Biotherapeutics, you can compare the effects of market volatilities on Phathom Pharmaceuticals and Arcutis Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Phathom Pharmaceuticals with a short position of Arcutis Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Phathom Pharmaceuticals and Arcutis Biotherapeutics.

Diversification Opportunities for Phathom Pharmaceuticals and Arcutis Biotherapeutics

0.04

Correlation Coefficient

Phathom Pharmaceuticals  Arcutis Biotherapeutics

Significant diversification

The 3 months correlation between Phathom and Arcutis is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding Phathom Pharmaceuticals and Arcutis Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Arcutis Biotherapeutics and Phathom Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Phathom Pharmaceuticals are associated (or correlated) with Arcutis Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Arcutis Biotherapeutics has no effect on the direction of Phathom Pharmaceuticals i.e., Phathom Pharmaceuticals and Arcutis Biotherapeutics go up and down completely randomly.

Pair Corralation between Phathom Pharmaceuticals and Arcutis Biotherapeutics

Given the investment horizon of 90 days Phathom Pharmaceuticals is expected to generate 4.46 times more return on investment than Arcutis Biotherapeutics. However, Phathom Pharmaceuticals is 4.46 times more volatile than Arcutis Biotherapeutics. It trades about 0.19 of its potential returns per unit of risk. Arcutis Biotherapeutics is currently generating about -0.03 per unit of risk. If you would invest  258.00  in Phathom Pharmaceuticals on May 4, 2025 and sell it today you would earn a total of  577.00  from holding Phathom Pharmaceuticals or generate 223.64% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Phathom Pharmaceuticals  vs.  Arcutis Biotherapeutics

Phathom Pharmaceuticals

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Phathom Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Phathom Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Arcutis Biotherapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Arcutis Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Arcutis Biotherapeutics is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Phathom Pharmaceuticals and Arcutis Biotherapeutics

The main advantage of trading using opposite Phathom Pharmaceuticals and Arcutis Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Phathom Pharmaceuticals position performs unexpectedly, Arcutis Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcutis Biotherapeutics will offset losses from the drop in Arcutis Biotherapeutics' long position.

The idea behind Phathom Pharmaceuticals and Arcutis Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.